Methadone is used for opioid use disorder because it is a long-acting opioid that occupies the same brain receptors as heroin or fentanyl, keeping withdrawal symptoms and cravings at bay for a full 24 hours on a single dose. Unlike short-acting opioids that produce rapid highs and crashes, methadone’s slow, steady activity stabilizes brain chemistry without producing euphoria at therapeutic doses. This combination of craving suppression, withdrawal prevention, and reduced overdose risk is why it has remained a cornerstone of addiction treatment since the 1960s.
How Methadone Works in the Brain
Methadone is a full agonist at the mu-opioid receptor, the same receptor targeted by heroin, oxycodone, and fentanyl. When it binds to that receptor, it activates it enough to relieve withdrawal and quiet cravings, but because it reaches the brain gradually and stays there for hours, it doesn’t create the sharp spike of pleasure that drives compulsive use. The average half-life is about 24 hours, though it can range anywhere from 8 to 59 hours depending on the person. After a dose, blood levels peak in two to four hours, then slowly taper off, providing a full day of stability without overmedication or withdrawal.
At adequate maintenance doses, methadone also creates what’s called cross-tolerance. Because it keeps the mu-opioid receptors steadily occupied, other opioids can’t bind as effectively. If someone on a stable methadone dose uses heroin, the expected high is blunted or absent. This pharmacological blockade removes one of the primary incentives to keep using. Doses above 60 mg per day are most effective for this purpose, with the typical maintenance range falling between 60 and 120 mg. Patients on doses above 60 mg are significantly less likely to use or inject illicit drugs compared to those on lower doses.
How It Compares to Other Treatments
Buprenorphine (sold under brand names like Suboxone) is the other widely used medication for opioid use disorder, but it works differently. Buprenorphine is a partial agonist, meaning it activates the opioid receptor only partially, which gives it a ceiling effect on both its therapeutic action and its risks. Methadone, as a full agonist, can be titrated higher without hitting that ceiling, making it better suited for people with severe dependence or those who haven’t responded to buprenorphine.
Treatment retention data reflects this. In one study comparing the two medications after hospital-initiated treatment, 35% of methadone patients remained in outpatient care at 12 weeks, compared to 13% of buprenorphine patients. The gap was visible early: at 30 days, retention was 39% for methadone versus 26% for buprenorphine. Higher retention matters because staying in treatment is the single strongest predictor of long-term recovery.
Reduction in Overdose Deaths and Other Risks
The most important reason methadone remains central to opioid use disorder treatment is its effect on mortality. A large systematic review and meta-analysis published in JAMA Psychiatry found that people with opioid dependence had substantially lower risk of death from overdose, suicide, cardiovascular disease, and alcohol-related causes while receiving opioid agonist treatment compared to periods when they were not in treatment. The protective effect extended to people recently released from incarceration, a population at extremely high risk of fatal overdose.
Beyond overdose prevention, methadone maintenance reduces the spread of blood-borne infections. Because it decreases injection drug use, it lowers the chance of sharing needles. One study tracking hepatitis C transmission found that methadone maintenance cut the odds of new infection by roughly half. The longer people stayed in treatment, the stronger the protection became, with each additional six months of enrollment further reducing the risk.
What Daily Treatment Looks Like
Methadone for opioid use disorder can only be dispensed through federally regulated opioid treatment programs, commonly called methadone clinics. This is different from buprenorphine, which can be prescribed from a regular doctor’s office. For most patients, treatment begins with daily supervised visits to the clinic, where a nurse watches them take their dose.
As patients stabilize, they can earn take-home doses. Under current federal guidelines, clinicians can authorize up to 7 take-home doses within the first two weeks of treatment, up to 14 doses between days 15 and 30, and up to 28 doses (a full month’s supply) after 31 days. These decisions are individualized. The prescribing clinician evaluates factors like the absence of active substance use, regular attendance, no recent diversion concerns, and whether the medication can be safely stored at home. The daily clinic requirement has historically been one of the biggest barriers to treatment, and the expanded take-home rules have made methadone significantly more accessible.
Use During Pregnancy
Methadone has been used to treat opioid use disorder during pregnancy since the early 1970s, making it one of the longest-studied medications in this population. Untreated opioid dependence during pregnancy carries serious risks, including stillbirth, preterm delivery, and repeated cycles of withdrawal that can harm the fetus. Methadone stabilizes both the mother and the developing baby by preventing those dangerous fluctuations.
Some studies have found modestly higher rates of preterm delivery and low birth weight with methadone use, though these outcomes are more strongly linked to using opioids outside of medical supervision or at higher-than-recommended doses. The most common concern is neonatal abstinence syndrome (NAS), a set of withdrawal symptoms the baby can experience after birth. NAS symptoms include irritability, excessive crying, poor feeding, tremors, and disrupted sleep. Not all exposed babies develop NAS, and those who are breastfed tend to have shorter hospital stays and less need for treatment.
Heart Rhythm Monitoring
One safety consideration specific to methadone is its potential to affect the heart’s electrical rhythm. At higher doses, methadone can prolong a measurement called the QT interval, which in rare cases can trigger a dangerous heart rhythm. A SAMHSA expert panel recommended that patients with risk factors for heart rhythm problems, such as a personal or family history of arrhythmias, episodes of fainting, or use of other medications that affect heart rhythm, should receive a baseline electrocardiogram (EKG) within 30 days of starting treatment. Additional EKGs are recommended annually or whenever the dose exceeds 120 mg per day. If the QT interval reaches 500 milliseconds or above, clinicians typically consider reducing the dose or switching to an alternative medication. For most patients on standard doses, this risk is low but worth monitoring.